CVRx trims Barostim revenue forecast as quarterly sales slip 6%

CVRx has reduced its revenue expectations for 2026 after reporting a third-quarter sales decline. Revenue for the period was $13.8M, down 6%, and the net loss came to $14.2M. The company sells Barostim, a neuromodulation device for heart failure.

The full-year forecast is now $56-57M, compared with the earlier $58-60M. The floor of the range falls by $2M and the ceiling by $3M. CVRx linked the change to weaker output from its commercial team and to a long-running difficulty with a large payer.

Coverage did move in the company's favour. A second Medicare Advantage plan issued a Barostim policy effective 17 July 2026. By CVRx's account, the two policies together reach about 21% of Medicare Advantage enrollment, which implies most of that market still lacks a Barostim-specific policy.

The information available does not name the payer behind the continuing problem or set out the terms of the new policy. It is therefore unclear how much the added coverage offsets the payer pressure, or when it might show up in sales.